37
Avoid/minimize use of
other hepatotoxic agents
(eg, acetaminophen).
Hepatoxicity may
warrant interrupting
therapy.
Both drugs listed below
are associated with drug
interactions that can be
life threatening.
Typically, NOT
warranted or
recommended for
antileishmanial
treatment during
pregnancy.
Can be taken with or
without food.
(Also see above.)
See above. Generally considered
compatible.
On principle,
interruption of
breastfeeding may be
prudent.
To minimize GI
symptoms, take with
food; gastric acidity
required. (Also see
above.)
See above. Selection of a
different drug or
interruption of
breastfeeding may
be prudent.
To minimize GI
symptoms, take with
food and use divided
daily dosing (see Recs.
78-79).
Encourage fluid intake
if vomiting/diarrhea.
Female patients
with reproductive
potential
k
should
have a negative
pretreatment
pregnancy
test, should
use effective
contraception
during and for
5 months aer
treatment, and
should not rely
on hormonal
contraception if
vomiting/diarrhea.
Breastfeeding not
recommended
during or for
5 months aer
treatment (see Recs.
78-79).
Not FDA-
approved for
patients <12 years
of age or <30 kg.
(See Recs. 78-79)
regarding
considerations for
children and other
special populations.
Contraindicated
in patients with
Sjögren- Larsson
Syndrome
(congenital
ichthyosis).
Mitigation and
Management
Approaches
d,f
Pregnant
Patients
f,g
Breastfeeding
Patients
f,h
Comments
